Abstract Number: 1945 • ACR Convergence 2022
Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia
Background/Purpose: Juvenile Fibromyalgia Syndrome (JFS) is a disabling condition characterized by widespread musculoskeletal pain, fatigue and mood disturbances, which impact significantly on patients' quality of…Abstract Number: 0728 • ACR Convergence 2022
Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery
Background/Purpose: Fibromyalgia syndrome (FMS) is a condition characterized by diffuse, widespread, persistent musculoskeletal pain in multiple regions of the body. While FMS is more prevalent…Abstract Number: 2233 • ACR Convergence 2022
Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia
Background/Purpose: Fibromyalgia is a debilitating pain condition that affects roughly 12 million people in the United States. Although preliminary diagnostic criteria have been established by…Abstract Number: 0733 • ACR Convergence 2022
Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis
Background/Purpose: Patient global assessment (PATGL) is a component of DAS28 (disease activity score 28) and CDAI (clinical disease activity index) to assess patients with rheumatoid…Abstract Number: 2235 • ACR Convergence 2022
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management in a Decentralized Trial
Background/Purpose: Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for management of fibromyalgia (FM). Acceptance and Commitment Therapy (ACT), a form of CBT, has…Abstract Number: 0122 • ACR Convergence 2021
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
Background/Purpose: Recommendations for fibromyalgia management include both pharmacologic and nonpharmacologic treatments. Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for fibromyalgia management, though access…Abstract Number: 0123 • ACR Convergence 2021
Vestibulocortical Stimulation with Caloric Irrigation Reduces Pain and Improves Subjective Well-Being in Fibromyalgia: An Open-Label Pilot Trial
Background/Purpose: Safe and effective therapies for fibromyalgia (FM) remain a major unmet clinical need. Vestibulocortical stimulation (VCS) via caloric irrigation is a safe, inexpensive, non-invasive…Abstract Number: 0125 • ACR Convergence 2021
Body Mass Composition in Post-menopausal Women with Fibromyalgia: Preliminary Results from a Cross-sectional Monocentric Study
Background/Purpose: Fibromyalgia (FM) is characterized by chronic musculoskeletal widespread pain, fatigue, sleep disturbances and functional symptoms. The primary endpoint of our study aimed to determine…Abstract Number: 0126 • ACR Convergence 2021
Prevalence of Dyslipidemia in Fibromyalgia: A Single Center Case Control Study from South India
Background/Purpose: Fibromyalgia (FM), a condition characterized by chronic widespread pain, has implications beyond functional disability. FM has been associated with an increased risk of cardiovascular…Abstract Number: 0127 • ACR Convergence 2021
Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
Background/Purpose: Interleukin-1 receptor antagonist (IL-1Ra) variable number of tandem repeats (VNTR) polymorphism is a known to influence the production of IL-1Ra and has been considered…Abstract Number: 0474 • ACR Convergence 2021
Correlation of Fibromyalgia Survey Questionnaire and Quantitative Sensory Testing Among Patients with Active Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) commonly demonstrate disordered pain processing, termed central sensitization (CS). CS is typically measured using quantitative sensory testing (QST), which…Abstract Number: 0475 • ACR Convergence 2021
Quantitative Analysis of Gender and Racial Disparities in Randomized Controlled Trials of Fibromyalgia
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, mood disorders, fatigue, and cognitive and sleep disturbance. Mainstay treatments include tricyclic antidepressants,…Abstract Number: 0476 • ACR Convergence 2021
Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis
Background/Purpose: Fibromyalgia (FM) is characterized by a constellation of symptoms that are often poorly responsive to current treatments, and patients are increasingly turning to medical…Abstract Number: 0477 • ACR Convergence 2021
TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain, fatigue, and nonrestorative sleep, a symptom constellation suggestive of a pathological disturbance in central pain processing…Abstract Number: 0659 • ACR Convergence 2021
Understanding the Rheumatologic Population We Serve Through Objective Analysis of Referrals and Diagnoses: Does Perception Match Actual Data?
Background/Purpose: Healthcare access in our Rheumatology Department is challenging. Fibromyalgia is perceived to occupy a large portion of clinic visits, leading to increased wait times…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 25
- Next Page »
